Using these methods, we have developed a potent and effective BiCisCAR against NB expressing GPC2 or CD276 that showed prolonged persistence, less exhaustion, and more central memory properties in vivo, and that will be developed as a new adoptive immunotherapeutic for patients with high-risk NB. Here, CD276 is linked to neuroblastoma.